Welcome, visitor! [ Login

Dragon Lists on the TSX Under Symbol ‘DDD’


Dragon Pharmaceuticals Inc. is pleased to announce that it has received final approval from the Toronto Stock Exchange (TSX) for listing the Company’s shares on the TSX. The shares will be traded under the symbol DDD commencing today. Dragon’s shares will continue to trade on the NASDAQ OTC BB under the symbol DRUG. Maison Placements Canada, Inc. acted as the sponsor for the Company’s TSX listing.

“This is a tremendous step for us as we seek to raise our corporate profile in the investment community,” said Longbin Liu, CEO of Dragon. “Our listing on the TSX will significantly support our efforts to increase the institutional following of our company.”

The TSX has listed Dragon as a technology company. Dragon has developed a proprietary DNA vector technology platform that can be used to construct a wide range of recombinant, or genetically engineered, human protein cell lines. The cell lines developed with Dragon’s technology are capable of producing, at commercial volumes, premium quality proteins at exceptionally high yields and low per unit production costs.

Dragon has validated its proprietary technology platform with the commercial production of Epoetin Alfa (EPO) at the Company’s GMP-certified manufacturing facility in Nanjing, China. Dragon is one of the world’s largest producers of EPO, and is marketing the product in China, Egypt, India and Peru for use in anemia related to chronic renal failure. The Company has initiated, through its 11 international licensees, regulatory submissions for marketing approval throughout Central and Eastern Europe, Southeast Asia, Latin America and the Middle East. Dragon has completed clinical trials and submitted its application to the Chinese State Drug Administration for use of EPO in surgery-related anemia and is currently conducting Phase II/III clinical trials in chemotherapy-related anemia.

The Company is applying its technology platform to other drugs in its development pipeline, which include slow-release EPO, thrombopoietin, granulocyte-colony stimulating factor, and insulin, as well as to its novel drug discovery candidates.

No Tags

4060 total views, 4 today